FRET-based assay to screen inhibitors of HIV-1 reverse transcriptase and nucleocapsid protein
Author(s) -
Kamal Kant Sharma,
Frédéric Przybilla,
Tobias Restle,
Julien Godet,
Yves Mély
Publication year - 2016
Publication title -
nucleic acids research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 9.008
H-Index - 537
eISSN - 1362-4954
pISSN - 0305-1048
DOI - 10.1093/nar/gkv1532
Subject(s) - reverse transcriptase , förster resonance energy transfer , biology , dna , rna , primer (cosmetics) , microbiology and biotechnology , nevirapine , rna directed dna polymerase , virology , human immunodeficiency virus (hiv) , biochemistry , fluorescence , chemistry , gene , antiretroviral therapy , viral load , physics , organic chemistry , quantum mechanics
During HIV-1 reverse transcription, the single-stranded RNA genome is converted into proviral double stranded DNA by Reverse Transcriptase (RT) within a reverse transcription complex composed of the genomic RNA and a number of HIV-1 encoded proteins, including the nucleocapsid protein NCp7. Here, we developed a one-step and one-pot RT polymerization assay. In this in vitro assay, RT polymerization is monitored in real-time by Förster resonance energy transfer (FRET) using a commercially available doubly-labeled primer/template DNA. The assay can monitor and quantify RT polymerization activity as well as its promotion by NCp7. Z-factor values as high as 0.89 were obtained, indicating that the assay is suitable for high-throughput drug screening. Using Nevirapine and AZT as prototypical RT inhibitors, reliable IC50 values were obtained from the changes in the RT polymerization kinetics. Interestingly, the assay can also detect NCp7 inhibitors, making it suitable for high-throughput screening of drugs targeting RT, NCp7 or simultaneously, both proteins.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom